株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

多血小板血漿の世界市場:タイプ、ソース、アプリケーション、エンドユーザー、地理別の成長率、動向および予測

Platelet Rich Plasma Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 661049
出版日 ページ情報 英文 114 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.55円で換算しております。
Back to Top
多血小板血漿の世界市場:タイプ、ソース、アプリケーション、エンドユーザー、地理別の成長率、動向および予測 Platelet Rich Plasma Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 114 Pages
概要

多血小板血漿市場は、予測期間中に14%のCAGRで成長すると見込まれています。デキストロースプロラセラピーと同様に、多血小板血漿(PRP)プロラセラピーは、治癒を促進するように設計された注射方法です。多血小板血漿は、少なくとも7つの増殖因子を含むベースラインレベルを超える血小板濃度を有する自己血液として定義されます。

当レポートでは、世界の多血小板血漿市場を調査し、全体的な市場動向、タイプ、ソース、アプリケーション、エンドユーザー、地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 市場のダイナミクス

  • 市場の成長要因
    • スポーツ傷害の発生率
    • アンドロゲン性脱毛症患者数の増加
    • 様々な治療領域における多血小板血漿の使用の拡大
    • 関節炎の有病率
  • 市場の阻害要因
    • 厳格な規制政策
    • 高格な血漿療法
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • タイプ別
    • 純粋なPRP
    • 白血球に富むPRP
    • 純粋な血小板に富むフィブリン
    • 白血球に富むフィブリン
  • ソース別
    • 自己由来
    • 同種異系
  • アプリケーション別
    • 整形外科
    • 皮膚科学
  • エンドユーザー別
    • 病院・診療所
    • 研究機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • その他の地域

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Bio Product Laboratory Ltd (BPL)
  • Biolife Plasma Services
  • Biotest
  • Cambryn Biologics LLC
  • China Biologic Products, Inc.
  • CSL Ltd.
  • Grifols International SA
  • Kedrion SPA
  • LFB SA
  • Octapharma など

第10章 市場の将来展望

目次
Product Code: 60477

Market Overview

The global platelet-rich plasma market is expected to register a CAGR of approximately 14% over the forecast period. The key factors that are augmenting the growth of the market include rising incidences of sports injuries, increasing number of androgenic alopecia patients, growing use of platelet-rich plasma in various therapeutic areas, and rise in the prevalence of arthritis.

Osteoarthritis (OA) is the most common form of chronic disorder of the joints, and it has some detrimental effects on the quality of life of the patients. Progressive cartilage destruction, osteophyte formation, and subchondral sclerosis are characteristic to osteoarthritis. Platelet-rich plasma (PRP) is an autologous concentration of a high number of platelets in a small volume of plasma. PRP is prepared to centrifuge blood. In knee OA, PRP injections target to promote cartilage repair in order to relieve symptoms of osteoarthritis, hence delaying the need for joint replacement surgery.

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

Scope of the Report

As per the scope of the report, platelet-rich plasma (PRP) prolotherapy, like dextrose prolotherapy, is a method of injection designed to stimulate healing. Platelet-rich plasma is defined as autologous blood with concentrations of platelets above baseline levels, which contains at least seven growth factors.

Key Market Trends

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US government's initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Competitive Landscape

Companies, such as Biotest AG, China Biologic Products Inc., CSL Ltd, Octapharma AG, and LFB SA, are some of the key players operating in the global platelet-rich plasma market. With the advancement in technology, new players are expected to come in the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Sports Injuries
    • 4.2.2 Increasing Number of Androgenic Alopecia Patients
    • 4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas
    • 4.2.4 Rising Prevalence of Arthritis
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Policies
    • 4.3.2 High Prices of Plasma Therapy
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Pure PRP
    • 5.1.2 Leukocyte-rich PRP
    • 5.1.3 Pure Platelet-rich Fibrin
    • 5.1.4 Leukocyte-rich Fibrin
  • 5.2 By Source
    • 5.2.1 Autologous
    • 5.2.2 Allogenic
  • 5.3 By Application
    • 5.3.1 Orthopedic
      • 5.3.1.1 Arthritis
      • 5.3.1.2 Chronic Tendinitis
      • 5.3.1.3 Bone Repair and Regeneration
    • 5.3.2 Dermatology
      • 5.3.2.1 Androgenic Alopecia
      • 5.3.2.2 Plastic Surgery
      • 5.3.2.3 Cardiac Muscle Injury
      • 5.3.2.4 Dental
      • 5.3.2.5 Nerve Injury
      • 5.3.2.6 Other Applications
    • 5.3.3 By End User
      • 5.3.3.1 Hospitals and Clinics
      • 5.3.3.2 Research Institutes
      • 5.3.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bio Product Laboratory Ltd (BPL)
    • 6.1.2 Biolife Plasma Services
    • 6.1.3 Biotest AG
    • 6.1.4 Cambryn Biologics LLC
    • 6.1.5 China Biologic Products Inc.
    • 6.1.6 CSL Ltd
    • 6.1.7 Grifols International SA
    • 6.1.8 Kedrion SpA
    • 6.1.9 LFB SA
    • 6.1.10 Octapharma AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top